Cargando…
Liquid biopsy for the assessment of adrenal cancer heterogeneity: where do we stand?
Almost 10 years have passed since the first attempts of liquid biopsy aimed at the characterisation of tumor cells present in the bloodstream from a regular sample of peripheral blood were performed. Liquid biopsy has been used to characterise tumor heterogeneity in various types of solid tumors inc...
Autores principales: | Perge, Pál, Nyirő, Gábor, Vékony, Bálint, Igaz, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385753/ https://www.ncbi.nlm.nih.gov/pubmed/35552979 http://dx.doi.org/10.1007/s12020-022-03066-z |
Ejemplares similares
-
Liquid Biopsies in Sarcoma Clinical Practice: Where Do We Stand?
por: van der Laan, Pia, et al.
Publicado: (2021) -
Where do conventional OADs stand
por: Sahay, Rakesh Kumar, et al.
Publicado: (2012) -
Vaccines for COVID-19: Where do we stand in 2021?
por: Sharma, Ketaki, et al.
Publicado: (2021) -
Virtual biopsy in abdominal pathology: where do we stand?
por: Defeudis, Arianna, et al.
Publicado: (2023) -
Where Do We Stand?
Publicado: (1891)